New drug cocktail aims to stop transplant rejection in blood cancer patients
NCT ID NCT06315309
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times
Summary
This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers like leukemia. About 29 adults aged 18-60 who have a matched donor will receive the treatment and be followed for one year. The goal is to see if more patients can stay alive and free of GVHD or cancer relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.